Eli Lilly's CEO and Zyprexa earn accolades
INDIANAPOLIS - Randall Tobias, Eli Lilly and Co.'s chairman and CEO, is the top manager for 1997, and Zyprexa® (olanzapine), Lilly's new product for schizophrenia, is one of the year's top products, according to "Business Week."
INDIANAPOLIS - Randall Tobias, Eli Lilly and Co.'s chairman and CEO, is the top manager for 1997, and Zyprexa® (olanzapine), Lilly's new product for schizophrenia, is one of the year's top products, according to "Business Week."
The business and finance magazine said it considered financial and share-price performance when it chose its list of top managers for the year.
Under Tobias' guidance, the company's market value rose from $14 billion to $77 billion.
The company also aggressively battered the pharmaceutical market with new products - five within the last two years - which boosted the company's stock price by more than 90% during 1997.
At press time, the company's share price was listed at $663â8 per share on the New York Stock Exchange.
Zyprexa, cleared for marketing by the FDA in October 1996, garnered $550 million in sales over the course of its first year on the market.
"Just as Prozac has become an important product for the treatment of depression, Zyprexa has become an important tool in treating symptoms of schizophrenia," said August Watanabe, M.D., Lilly's executive vice president of science and technology.
The medicine has been approved in more than 50 countries and prescribed to more than 770,000 patients. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
